Download Free Neuroprotection Book in PDF and EPUB Free Download. You can read online Neuroprotection and write the review.

Neuroprotection in Alzheimer's Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer's disease will pave the path to better disease management and novel therapeutics. - Comprehensive reference detailing neuroprotection in Alzheimer's Disease, with details on nerve cell protection and new advances in disease management - Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development - Edited by one of the leading researchers in Alzheimer's Disease
A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.
Discovery and Development of Neuroprotective Agents from Natural Products draws together global research on medicinal agents from natural sources as starting points for the design of neuroprotective drugs. From the prediction of promising leads and identification of active agents to the extraction of complex molecules, the book explores a range of important topics to support the development of safer, more economical therapeutics for these increasingly prevalent diseases. Beginning with an overview of current developments in the field, the book goes on to explore the identification, extraction and phytochemistry of such neuroprotective agents as antioxidants, biophenols and naturally occurring anti-inflammatory steroid analogues. Specific natural sources of bioactive agents are reviewed, and the development of these agents into therapeutics for a number of specific neurological disorders, including Alzheimer's disease, Parkinson's disease and ischemic brain stroke, are discussed. Combining the expertise of specialists from around the world, this in the Natural Products Drug Discovery series aims to support and encourage researchers in the investigation of natural sources as starting points for the development of standardized, safe and effective neuroprotective drugs. - Features chapters written by active researchers and leading global experts deeply engaged in the research field of natural product chemistry for drug discovery - Includes comprehensive coverage of cutting-edge research advances in the design of drugs from natural products targeted at different kinds of neurodegenerative diseases - Offers a practical review of identification, isolation and extraction techniques to support medicinal chemists in the lab
The perioperative care of individuals with neurologic compromise is critically important, yet it is only one dimension of the rich relationship between anaesthesiology and the neurosciences. The mechanism of everyday therapeutic interventions such as anaesthesia and analgesia is exciting neuroscience in its own right. At the new frontier of outcomes studies lies the question of how the perioperative period might impact the brain. For example, questions related to anaesthetic neurotoxicity, delirium, and cognitive dysfunction pose critical challenges for the field. The Oxford Textbook in Neuroscience and Anaesthesiology addresses the exciting field of neuroanaesthesiology in a new and stimulating way. In twenty eight chapters, the neuroscientific basis of anaesthesiology, the full spectrum of clinical neuroanaesthesia, and the care of neurologic patients undergoing non-neurologic surgery are explored in one comprehensive textbook for the first time. The first section considers the neural mechanisms of general anaesthetics, cerebral physiology, the neurobiology of pain, and more. The second section explores the care of patients with neurologic disease in the operating room or intensive care unit. These clinical chapters systematically treat the perioperative considerations of both brain and spine surgery, and provide introductions to neurocritical care and pediatric neuroanaesthesia. The final section outlines the care of neurologic patients undergoing non-neurologic surgery. It examines key connections of neurology and anaesthesiology, examining how conditions such as dementia, stroke, or epilepsy interface with the perioperative period. Each chapter has been carefully crafted to be concise yet highly informative, reflecting the cutting edge of neuroscience and neuroanaesthesiology. This international textbook gathers the best available expertise of authors and leaders worldwide. Includes access to online-only content, including more than 20 cases and more than 90 questions that can be used in presentations and teaching sessions. By activating your unique access code, you can access and use the material.
Neurological disease affects nearly 25%–30% of the world’s population, exerting enormous financial strain on the healthcare system. Estimated current costs are around $800 annual billion, and this number is expected to increase exponentially as the global population ages. As such, new and alternative neuroprotective strategies are urgently needed. This book examines some of the most promising approaches in neuroprotection as well as discusses current goals and prospects. Organized into three sections, chapters cover such topics as the use of cannabinoids, medicinal plants, and essential oils in Alzheimer’s and Parkinson’s; protein misfolding and the neuroprotective potential of vitamin E in cerebral ischemia; and potential new neurological treatments and their mechanisms of action.
Although the genomic era is no longer in its infancy, the life sciences are still facing questions about the role of endogenous proteins and peptides in homeostasis and pathologies. Delving into one of the most current fields of interest in biology and medicine, Neuropeptides in Neuroprotection and Neuroregeneration describes the impact of neuropeptides on neuroprotection and neuroregeneration. The book begins with chapters describing important features of the endogenous neuropeptide systems related to their formation, receptor signaling, and inactivation. It includes chapters focused on the design and development of peptide-like drugs (peptidomimetics). In addition, the book covers: General aspects regarding the biosynthesis, structures, and distribution of neuroactive peptides and their receptors Basic mechanisms for neuropeptide action, metabolism, as well as techniques for their detection and aspects essential for the cellular mechanisms underlying brain pathology Neuropeptides known for their impact in neurodegenerative and neuroprotective processes Fundamental aspects as well as recent progress in the development of peptidomimetics of neuroprotective and cognition-enhancing peptides
There is growing interest in the field of melatonin research regarding its neurobiological mechanisms as well as its repercussions in clinical practice. Melatonin: Therapeutic Value and Neuroprotection explores melatonin’s neuroprotective effects and discusses the therapeutic potential of melatonin and melatonin agonists in treating neurodegenerative diseases and other ailments. Topics include: The basic aspects of melatonin’s physiology, including its production, bioavailability, and metabolism The functional importance of melatonin receptors and their role in mediating the therapeutic effectiveness of melatonin in cancer Melatonin’s effect on the regulation of blood pressure, sleep, and circadian rhythms The cardioprotective role of melatonin The neuroprotective role in glaucoma, Alzheimer’s disease, Parkinson’s disease, and neurodegenerative diseases Use as a therapeutic agent for treating epilepsy and degenerative discs Treatment for obesity, diabetes mellitus, and other metabolic disorders Protective role in peri-natal hypoxic-ischemia The contributors also examine the discovery of a number of melatonergic agonists, their potential role as antioxidants, and their therapeutic applications in treating glaucoma, Parkinson’s disease, Alzheimer’s disease, primary insomnia, and psychiatric disorders. Opening new vistas in our understanding of etiology, pharmacotherapy, and treatment, the book is a significant milestone in our knowledge about advances in melatonin’s physiology and its therapeutic application in a number of disorders.
Neuroprotection has been placed on a firm scientific basis during the past decade due to an improved understanding of the molecular basis of neurological diseases and the knowledge that treatment of neurological disorders should not be merely symptomatic but preventative against the progression of the underlying disease, as well as regenerative. The Handbook of Neuroprotection serves as a comprehensive review of neuroprotection based on knowledge of the molecular basis of neurological disorders. Neuroprotective effects of older, established drugs, as well as new drugs in development, are well documented in this detailed volume, featuring the most cutting-edge and innovative methods currently in use. In-depth and authoritative, The Handbook of Neuroprotection features a compendium of vital knowledge aimed at providing researchers with an essential reference for this key neurological area of study.
This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects. .
"Neurodegenerative diseases are a complex heterogeneous group of diseases associated with site-specific premature and slow death of certain neuronal populations in brain and spinal cord tissues. For example, in Alzheimer disease, neuronal degeneration occu"